|
|
|
|
The clinical data suggest that levodopa either slows the progression of ParkinsonÆs disease or has a prolonged effect on the symptoms of the disease. In contrast, the neuro-imaging data suggest either that levodopa accelerates the loss of nigrostriatal dopamine nerve terminals or that its pharmacologic effects modify the dopamine transporter. The potential long-term effects of levodopa on ParkinsonÆs disease remain uncertain. |
|